Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia

Withdrawn before enrolling

Conditions studied: Schizophrenia

In brief

The goals of this study is to determine (1) if differences in D2/3 receptor affinity states exist between medication-free subjects with SCH (MF-S) compared with healthy controls (HC), (2) the degree to which pre- and post-synaptic factors contribute to increased striatal dopamine (DA) signaling in MF-S and (3) to test the hypotheses that optimal DA transmission in the dorsal caudate (DCA) is necessary for normal working memory (WM) function.

Key facts

Study ID
NCT03999190
Run by
NYU Langone Health
People needed
0
Starts
2019-07-01
Expected to finish
2025-07-01
Last updated by the study team
2020-05-29

Who can join

Age: 18 and older, up to 35. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.